Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Lisata Therapeutics, Inc. LSTA

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$170,000
▼ 83.0% YoY
$-16.6M
$-16.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 170,000.00
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.2 · Net income -16.6
25.0M50.0M-30.0M-60.0M
201020132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -10711.2% · Net ·
-5000%-10000%
201020172025
ROE
FY2025 · ROE -74.7%
50%-100%-200%
201020172025
Three returns, three denominators.

Each USD of equity lost 75 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -16.0
-20M-40M
201020172025
Net buybacks $ Dividends $
FY2014 · Dividends 0.0 · Net buybacks ·
150000300000
20102011201220132014

Total assetsUSD 17.7M
EquityUSD 14.9M
CashUSD 16.0M
Current ratio5.76×

Equity funds 84% of total assets.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
LSTA, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.0◌◌◌◌◌0.00.00.00.00.00.00.1
Operating income $B−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.1−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.1−0.0−0.0−0.0◌
Income tax $B−0.0−0.0−0.0−0.0−0.0−0.00.00.0−0.00.0−0.0−0.00.0−0.00.00.0
Net income $B−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.00.0−0.0−0.1−0.1−0.0−0.1−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0
EPS, diluted $−1.91−2.40−2.58−10.47−7.45−0.53−1.88−1.672.56−4.99−16.67−1.68−1.90−4.00−0.54−0.46
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout %———————————−0−0−1−0−1
ROE %−74.7−51.4−36.3−68.3−44.0−30.6−66.1−36.683.0−228.4◌−90.7−81.4−113.0−85.2−47.9
Shares out B0.010.010.010.010.060.020.010.010.010.010.010.040.030.160.110.06

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 62 reconciliationsAUDITED

Reconciled in 16 of the 16 fiscal years we could check. Nine checks were skipped: the share count is not tagged before 2016. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image